Deutsche Bank AG raised its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 36.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,189,964 shares of the biopharmaceutical company's stock after buying an additional 847,704 shares during the period. Deutsche Bank AG owned about 0.54% of Royalty Pharma worth $81,376,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently made changes to their positions in RPRX. Brooklyn Investment Group increased its holdings in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 876 shares during the last quarter. Allworth Financial LP increased its holdings in Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 877 shares during the last quarter. Riverview Trust Co increased its holdings in Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 1,186 shares during the last quarter. Fifth Third Bancorp increased its holdings in Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 997 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 376 shares during the last quarter. 54.35% of the stock is owned by institutional investors.
Royalty Pharma Trading Up 2.7%
NASDAQ:RPRX traded up $0.90 during midday trading on Friday, reaching $34.02. 4,933,445 shares of the stock traded hands, compared to its average volume of 3,347,310. The company has a fifty day moving average of $32.39 and a 200 day moving average of $29.99. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a market capitalization of $19.61 billion, a P/E ratio of 23.46, a PEG ratio of 2.31 and a beta of 0.49.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The company had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. On average, research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.
Royalty Pharma Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a dividend of $0.22 per share. The ex-dividend date is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.59%. Royalty Pharma's dividend payout ratio is currently 47.57%.
Analyst Ratings Changes
A number of research firms recently issued reports on RPRX. StockNews.com upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a report on Monday, May 12th. Morgan Stanley assumed coverage on shares of Royalty Pharma in a research note on Friday. They issued an "overweight" rating and a $51.00 target price for the company. Finally, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $42.50.
View Our Latest Research Report on Royalty Pharma
Royalty Pharma Profile
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Read More
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
